Drugs / BAY2010112
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01723475 | Nov 2012 → Jul 2018 | prostate neoplasm | Bayer | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAY2010112 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01723475 ↗ |
| Action | Deplete | “mediating T-cell killing of tumor cells” PMID 33172323 ↗ Nov 2020 |
| Route | Subcutaneous | “Subcutaneous (s.c.) administration once daily.” NCT01723475 ↗ |